

## **Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization**

DUBLIN, Feb. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will highlight clinical data on TD-1473, a novel, potent, and orally administered pan-Janus kinase (JAK) inhibitor designed to be intestinally restricted, in a poster presentation at the upcoming 12<sup>th</sup> Congress of the European Crohn's and Colitis Organization (ECCO). Researchers will present further data from the Company's completed Phase 1 study of single-ascending and multiple-ascending doses of TD-1473, results of which were first announced in June 2016. Theravance Biopharma is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases and is currently conducting a Phase 1b study of the compound in patients with moderate to severe ulcerative colitis. The 12<sup>th</sup> Congress of ECCO is being held in Barcelona, Spain, February 15-18, 2017.



Details of the TD-1473 poster presentation are as follows:

**Poster #469:** Safety, tolerability, and pharmacokinetics of the intestine-restricted oral pan-Janus kinase inhibitor TD-1473 after single and multiple oral doses in healthy subjects

**Poster Group:** Clinical Therapy and Observation

**Guided Poster Session:** Friday, February 17, 2017, 12:30 - 1:30 p.m. (CET)

### ***About Intestinally Restricted Pan-Janus (JAK) Kinase Inhibition***

JAK inhibitors function by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2) that play a key role in cytokine signaling. Inhibiting these JAK enzymes interferes with the JAK/STAT signaling pathway and, in turn, modulates the activity of a wide range of pro-inflammatory cytokines. JAK inhibitors are currently approved for the treatment of diseases, such as rheumatoid arthritis, myelofibrosis and psoriasis, and have demonstrated therapeutic benefit for patients with ulcerative colitis. However, these products are known to have side effects associated with systemic exposure.

TD-1473 is an internally-discovered JAK inhibitor that has demonstrated a high affinity for each of the JAK family of enzymes. Importantly, TD-1473 is an intestinally restricted treatment specifically designed to distribute adequately and predominantly to the tissues of the intestinal tract, treating inflammation in those tissues while minimizing systemic exposure. Theravance Biopharma is focused on utilizing targeted JAK inhibitors for potential treatment of a range of inflammatory intestinal diseases including ulcerative colitis, which affects roughly 700,000 patients in the United States.

### ***About Theravance Biopharma***

Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve lives of patients suffering from serious illness. Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved

in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.

In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the Closed Triple (the combination of fluticasone furoate, umeclidinium, and vilanterol), currently in development for the treatment of COPD and asthma.

For more information, please visit [www.theravance.com](http://www.theravance.com).

THERAVANCE<sup>®</sup>, the Cross/Star logo, and VIBATIV<sup>®</sup> are registered trademarks of the Theravance Biopharma group of companies.

*This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's strategies, plans and objectives, the Company's regulatory strategies and timing and results of clinical studies, the potential benefits and mechanisms of action of the Company's product and product candidates and the Company's expectations for product candidates through development, potential regulatory approval and commercialization. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of the press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates are unsafe or ineffective, the feasibility of undertaking future clinical trials for our product candidates based on FDA policies and feedback, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure. Other risks affecting Theravance Biopharma are described under the heading "Risk Factors" contained in Theravance Biopharma's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 9, 2016. In addition to the risks described above and in Theravance Biopharma's other filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.*

**Contact Information:**

Renee Gala  
Chief Financial Officer  
650-808-4045  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)

Tim Brons  
Vida Strategic Partners (media)  
646-319-8981  
[tbrons@vidasp.com](mailto:tbrons@vidasp.com)

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/theravance-biopharma-to->

[present-clinical-data-on-tv-1473-at-the-12th-congress-of-the-european-crohns-and-colitis-organization-300405998.html](https://www.theravance.com/newsroom/theravance-biopharma-presents-clinical-data-on-tv-1473-at-the-12th-congress-of-the-european-crohns-and-colitis-organization-300405998.html)

SOURCE Theravance Biopharma, Inc.

News Provided by Acquire Media